Literature DB >> 17868186

Guidelines for good pharmacoepidemiology practices (GPP).

.   

Abstract

Mesh：

Year:  2008        PMID： 17868186     DOI： 10.1002/pds.1471

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  52 in total

1.  Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases.

Authors:  S V Wang; P Verpillat; J A Rassen; A Patrick; E M Garry; D B Bartels
Journal:  Clin Pharmacol Ther       Date:  2016-03       Impact factor: 6.875

Review 2.  Ayurpharmacoepidemiology en Route to Safeguarding Safety and Efficacy of Ayurvedic Drugs in Global Outlook.

Authors:  Parikshit Debnath; Subhadip Banerjee; Anjan Adhikari; Pratip K Debnath
Journal:  J Evid Based Complementary Altern Med       Date:  2016-06-22

Review 3.  Utilization of health care databases for pharmacoepidemiology.

Authors:  Yasuo Takahashi; Yayoi Nishida; Satoshi Asai
Journal:  Eur J Clin Pharmacol       Date:  2011-08-02       Impact factor: 2.953

Review 4.  [Registry research in dermatology].

Authors:  S J Rustenbach; K Heyer; K Reppenhagen; M Augustin
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

Review 5.  A pathway to improved prospective observational post-authorization safety studies.

Authors:  Victor A Kiri
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

Review 6.  Methods in pharmacoepidemiology: a review of statistical analyses and data reporting in pediatric drug utilization studies.

Authors:  Marco Sequi; Rita Campi; Antonio Clavenna; Maurizio Bonati
Journal:  Eur J Clin Pharmacol       Date:  2012-07-26       Impact factor: 2.953

7.  Concomitant use of drugs known to cause interactions with oral antiplatelets-polypharmacy in acute coronary syndrome outpatients in Finland.

Authors:  Tuire Prami; Houssem Khanfir; Pål Hasvold; Eeva Reissell; Juhani Airaksinen; Ville Kytö
Journal:  Eur J Clin Pharmacol       Date:  2019-11-26       Impact factor: 2.953

Review 8.  Methods for assessing the preventability of adverse drug events: a systematic review.

Authors:  Katja Marja Hakkarainen; Karolina Andersson Sundell; Max Petzold; Staffan Hägg
Journal:  Drug Saf       Date:  2012-02-01       Impact factor: 5.606

9.  Comorbidities in patients with persistent or chronic immune thrombocytopenia.

Authors:  Cheryl Enger; Dimitri Bennett; Ulla Forssen; Patrick F Fogarty; Andrew T McAfee
Journal:  Int J Hematol       Date:  2010-07-24       Impact factor: 2.490

10.  Results of a survey on applied quality standards in non-interventional studies among the members of the German Association of Research-based Pharmaceutical Companies.

Authors:  Michael Hahn; Thorsten Ruppert; Thomas D Bethke; Ferdinand Hundt
Journal:  Ger Med Sci       Date:  2010-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.